BioSpace News Archive

Inozyme Pharma, Inc. today announced a regulatory update for its global development strategy of INZ-701 for the treatment of ENPP1 Deficiency following recent meetings with the United States (U.S.) Food and Drug Administration (FDA) and the Paediatric Committee (PDCO) of the European Medicines Agency (EMA).

Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.

Cybin Inc. today announced that it has partnered with Worldwide Clinical Trials (“Worldwide”), a global, full-service contract research organization (“CRO”) with deep expertise managing clinical trials for mental health conditions, including major depressive disorder.

EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.

Fortive Corporation today announced financial results for the second quarter 2023.

Matinas BioPharma Holdings, Inc. announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023.

CoImmune, Inc. today announced the publication of preclinical results with Synthetic Enzyme-Armed Killer (SEAKER) cells in solid tumor melanomas in the peer-reviewed journal Cancer Immunology Research.

PharmAbcine Inc. announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company’s novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).

AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1

Circle Pharma announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer.